JMPWA
MACK

JP Morgan Private Wealth Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,202
Closed -$119K – 1302
2017
Q2 		$119K Hold
12,202
– – ﹤0.01% 1182
2017
Q1 		$296K Hold
12,202
– – ﹤0.01% 1074
2016
Q4 		$392K Sell
12,202
-5,592
-31% -$238K ﹤0.01% 898
2016
Q3 		$889K Buy
17,794
+2,542
+17% +$106K 0.01% 618
2016
Q2 		$647K Sell
15,252
-1,195
-7% -$65.1K 0.01% 700
2016
Q1 		$1.08M Sell
16,447
-254
-2% -$13.3K 0.01% 540
2015
Q4 		$1.04M Hold
16,701
– – 0.01% 515
2015
Q3 		$1.12M Buy
16,701
+254
+2% +$20.7K 0.01% 447
2015
Q2 		$1.6M Sell
16,447
-4,130
-20% -$393K 0.02% 406
2015
Q1 		$1.92M Hold
20,577
– – 0.02% 388
2014
Q4 		$1.83M Sell
20,577
-5,415
-21% -$394K 0.02% 394
2014
Q3 		$1.79M Buy
+25,992
New +$1.39M 0.02% 394

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Private Wealth Advisors's MACK Position: Q3 2017 in Review

JP Morgan Private Wealth Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 12,202 shares — an estimated $119K sold.

JP Morgan Private Wealth Advisors first reported a position in MACK in Q3 2014 and held it in 12 quarters. The position peaked at $1.92M in Q1 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • JP Morgan Private Wealth Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 12,202 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $119K.
  • JP Morgan Private Wealth Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 12 quarters.
  • JP Morgan Private Wealth Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $1.92M in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.